-+ 0.00%
-+ 0.00%
-+ 0.00%

AstraZeneca's Imfinzi Combo Therapy Wins US FDA Nod for Bladder Cancer Treatment

MT Newswires·11/15/2026 01:26:23
Listen to the news
01:26 AM EST, 11/15/2026 (MT Newswires) -- The US Food and Drug Administration approved AstraZeneca's (AZN.L, AZN.ST) Imfinzi in combination with enfortumab vedotin as neoadjuvant therapy for patients with muscle-invasive bladder cancer who are unsuitable for, or have declined, cisplatin-based chemotherapy. The US clearance was supported by the drugmaker's Volga phase 3 study, where it showed a 49% decrease in disease progression risk, recurrence, not undergoing surgery, or death, compared with radical cystectomy with or without adjuvant treatment, according to a Nov. 13 release. The study also demonstrated that the Imfinzi combo reduced the risk of death by 42%, with its safety and tolerability consistent with its known safety profile. AstraZeneca added that the combo treatment is under evaluation in the European Union, Japan, and other countries.